<DOC>
	<DOCNO>NCT00121602</DOCNO>
	<brief_summary>The purpose study evaluate whether efficacy darbepoetin alfa SF equivalent darbepoetin alfa RB treatment anemia patient chronic kidney disease ( CKD ) receive hemodialysis .</brief_summary>
	<brief_title>Efficacy Study : Darbepoetin Alfa Treatment Anemia Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Diagnosis CKD receive hemodialysis great equal 3 month enrollment No prior exposure EPREX® NeoRecorman® Baseline hemoglobin ( Hb ) 10 13 g/dL On stable weekly every week intravenous ( IV ) subcutaneous ( SC ) darbepoetin therapy least 6 week prior screen ( stable define less 25 % change weekly dose change frequency ) Adequate iron store ( serum ferritin equal great 100 mg/L ) Before studyspecific procedure , appropriate write informed consent must obtain Scheduled receive kidney transplant Uncontrolled hypertension , define predialysis systolic blood pressure ( BP ) great 180 and/or diastolic BP great 110 Acute myocardial ischemia ; hospitalization congestive heart failure , myocardial infarction , deep vein thrombosis , cerebrovascular event ( stroke transient ischemic attack ) within 12 week enrollment Parathyroid hormone ( PTH ) level great 1500 pg/mL Major surgery within 12 week enrollment ( exclude vascular access surgery ) Currently receive antibiotic therapy systemic infection Known positive HIV antibody positive hepatitis B surface antigen Clinical evidence current malignancy and/or receive systemic chemotherapy/radiotherapy exception basal cell squamous cell carcinoma skin cervical intraepithelial neoplasia Red blood cell ( RBC ) transfusion within 8 week enrollment Androgen therapy within 8 week enrollment Systemic hematologic disease ( e.g. , sickle cell anemia , myelodysplastic syndrome , hematologic malignancy ; myeloma ; hemolytic anemia ) Any disorder may impact ( judgment investigator ) ability give inform consent participation study Pregnant breastfeed woman . All subject must practice adequate contraception ( judgment investigator ) throughout trial . Treatment investigational agent device within 30 day enrollment schedule receive investigational agent specify protocol course study Subject know sensitivity product administer dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Darbepoetin Alfa</keyword>
	<keyword>Clinical Trials</keyword>
	<keyword>Nephrology</keyword>
	<keyword>Amgen</keyword>
	<keyword>Chronic Kidney Disease ( CKD )</keyword>
</DOC>